Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Delayed Quote USD

OraSure Technologies, Inc. (OSUR)

Compare
2.9300
-0.0100
(-0.34%)
At close: April 11 at 4:00:00 PM EDT
2.9300
0.00
(0.00%)
After hours: April 11 at 4:05:05 PM EDT
Loading Chart for OSUR
  • Previous Close 2.9400
  • Open 2.9400
  • Bid 2.8800 x 100
  • Ask 2.9800 x 100
  • Day's Range 2.8850 - 2.9500
  • 52 Week Range 2.6900 - 5.5900
  • Volume 388,148
  • Avg. Volume 875,159
  • Market Cap (intraday) 227.041M
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2600
  • Earnings Date May 6, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.00

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

www.orasure.com

501

Full Time Employees

December 31

Fiscal Year Ends

Recent News: OSUR

View More

Performance Overview: OSUR

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

OSUR
18.84%
S&P 500 (^GSPC)
8.81%

1-Year Return

OSUR
49.22%
S&P 500 (^GSPC)
3.16%

3-Year Return

OSUR
57.10%
S&P 500 (^GSPC)
21.55%

5-Year Return

OSUR
72.92%
S&P 500 (^GSPC)
92.25%

Compare To: OSUR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OSUR

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    227.04M

  • Enterprise Value

    -26.12M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.17

  • Price/Book (mrq)

    0.55

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.49%

  • Return on Assets (ttm)

    -2.68%

  • Return on Equity (ttm)

    -4.64%

  • Revenue (ttm)

    185.83M

  • Net Income Avi to Common (ttm)

    -19.5M

  • Diluted EPS (ttm)

    -0.2600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    267.76M

  • Total Debt/Equity (mrq)

    3.56%

  • Levered Free Cash Flow (ttm)

    30.61M

Research Analysis: OSUR

View More

Company Insights: OSUR

Research Reports: OSUR

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.